Khaled Chatila, MD
Advanced Heart Failure and Transplant Cardiology · Galveston, TXNPI 1932395795
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Abbott at 33.6% of the total. Reporting peaked in 2019 at $1,725 and has fallen 88.4% since, to $201 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in TX, where the typical reported total is $11,093.
Across 106 payments — averaging $63.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boston Scientific$844
- Abiomed$714
- Biotronik Inc.$505
- Johnson & Johnson$371
- Nuwellis, Inc.$309
- plus $2K from 13 others
What the payments were for
- Speaking & faculty fees$2003%
- Travel & lodging$3615%
- Food & beverage$6,12392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 27 | $2,248 |
| Boston Scientific | 24 | $844 |
| Abiomed | 6 | $714 |
| Biotronik Inc. | 6 | $505 |
| Johnson & Johnson | 15 | $371 |
| Nuwellis, Inc. | 2 | $309 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $306 |
| Amgen | 3 | $267 |
| Vifor Pharma, Inc. | 1 | $200 |
| Cvrx, Inc. | 1 | $130 |
| ZOLL Circulation Inc | 1 | $129 |
| Novartis | 7 | $128 |
| Pfizer | 4 | $128 |
| Livanova USA, Inc. | 1 | $106 |
| Lexicon Pharmaceuticals, Inc. | 1 | $95 |
| Biosense Webster, Inc. | 1 | $89 |
| United Therapeutics Corporation | 1 | $85 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$1,181
- Impella$587
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$252
- Repatha$244
- LifeVest$214
- Veltassa$200
- AQUADEX SMARTFLOW CONSOLE$192
- HeartMate 3 Left Ventricular Dev$153
- Sentus$139
- Barostim Neo System$130
- TherOx DS2 Console$129
- Catheter$129
- Downstream Cartridge$129
- AMPLATZER Occluders$121
- Watchman$120
- Aquadex$117
- MitraClip$108
- XARELTO$107
- ProtekDuo$106
How this compares
$6,684 in reported general payments places this provider in the 40th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 25 | $585,468 |
| FarxigaDapagliflozin Propanediol | 192 | $161,591 |
| EntrestoSacubitril/Valsartan | 125 | $116,995 |
| EliquisApixaban | 90 | $65,431 |
| JardianceEmpagliflozin | 74 | $54,038 |
| VeltassaPatiromer Calcium Sorbitex | 14 | $21,283 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $11,740 |
| Milrinone Lactate | 12 | $3,202 |
| Metoprolol Succinate | 140 | $2,137 |
| Bumetanide | 38 | $2,074 |
| Spironolactone | 232 | $2,074 |
| Furosemide | 173 | $1,483 |
| Carvedilol | 87 | $1,142 |
| Eplerenone | 17 | $1,077 |
| Potassium Chloride | 38 | $730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $128 | $650,900115 claims |
| NovartisEntresto | $128 | $116,995125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Galveston
- Wissam KhalifeGalveston$17K
- Shareef MansourGalveston$4K
- Robert GottliebDallas$717K
- Albert HicksTemple$613K
- Allen AndersonSan Antonio$413K
- Martin BerkDallas$379K
- Aasim AfzalPlano$336K
- Kunjan BhattAustin$324K
- Barry TrachtenbergHouston$306K
- Shelley HallDallas$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.